Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

1.33
-0.0800-5.67%
Post-market: 1.330.00000.00%16:05 EDT
Volume:395.08K
Turnover:522.82K
Market Cap:19.72M
PE:-1.42
High:1.40
Open:1.40
Low:1.27
Close:1.41
Loading ...

Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.

Dow Jones
·
23 Dec 2024

Positive Phase 1 Results of VYN202 Bolster VYNE Therapeutics’ Buy Rating

TIPRANKS
·
23 Dec 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data

TIPRANKS
·
23 Dec 2024

VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor

MT Newswires Live
·
23 Dec 2024

VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial

TIPRANKS
·
23 Dec 2024

Vyne Therapeutics Inc - Vyn202 Shows Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
23 Dec 2024

Vyne Therapeutics Reports Positive Top-Line Phase 1a Mad Data for Vyn202, Its Novel Bd2-Selective Bet Inhibitor

THOMSON REUTERS
·
23 Dec 2024

Vyne Therapeutics Inc - No Serious Adverse Events or Discontinuations Reported

THOMSON REUTERS
·
23 Dec 2024

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

GlobeNewswire
·
23 Dec 2024

VYNE Therapeutics Sees Strong Shareholder Support for Growth

TIPRANKS
·
13 Dec 2024

BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target

MT Newswires Live
·
18 Nov 2024

Vyne Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $8

THOMSON REUTERS
·
18 Nov 2024

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

TIPRANKS
·
18 Nov 2024

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
09 Nov 2024

Vyne Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.

Dow Jones
·
08 Nov 2024

VYNE Therapeutics: Robust Pipeline and Financial Stability Underpin Buy Rating

TIPRANKS
·
07 Nov 2024

VYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy Rating

TIPRANKS
·
07 Nov 2024

VYNE Therapeutics Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $121.000K Beat $110.000K Estimate

Benzinga
·
07 Nov 2024

VYNE Therapeutics Q3 EPS $(0.29) Misses $(0.23) Estimate, Sales $121.00K Beat $110.00K Estimate

Benzinga
·
07 Nov 2024